MYF5 and neoplasm: By contrast, the mid-differentiated myf5-GFP+/mylz2-mCherry+ ICN1-expressing ERMS cells could also now robustly engraft a tumor (p < 0.01; Figures 2E–2H and S2F– S2J; Table S2).